4 September 2023

Physiomics plc

("Physiomics" or "the Company")

Senior Management Update

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce the hiring of a new member of its senior management team.  Effective today, Dr Peter Sargent will be joining the Company as Chief Operating Officer ("COO").

Prior to joining us, Dr Sargent held a senior management role at global consultancy business Syneos Health Inc (NASDAQ: SYNH), leading large teams of professionals and servicing a variety of clients in the biopharmaceuticals space.  Among his earlier roles, Dr Sargent has also been Head of Business Development for the UK's National Institute for Health and Care Research (NIHR), leading a team supporting global life science businesses access to funding and research infrastructure in the UK.

The COO role will help to formulate the Company's overall business strategy and play a pivotal role in driving its execution.  The initial focus will be to strengthen the operational performance of the Company and in particular drive the key priorities announced during the Company's recent placing, namely:

·    further expansion and diversification of its client base;

·    expansion of its consulting business into the adjacent area of pharmaceutical biostatistics services; and

·    exploration of opportunities around its personalised oncology software offering.

Dr Sargent will join as a key member of the Company's senior leadership team (but not as a board director) and will report directly to Dr Jim Millen.  The hiring of Dr Sargent forms part of a strategy to revert to a more traditional board structure where the roles of Executive Chairman and CEO are separated. 

Executive Chairman & CEO, Dr Jim Millen, commented:

"I am delighted that Physiomics has been able to attract a candidate of the calibre of Dr Peter Sargent, who joins us with significant experience of building service businesses in the biopharmaceutical sector.  Peter will work closely with myself and my senior management team to set and drive forwards the Company's key business priorities and I look forward to him making a significant positive impact."

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

This announcement is released by Physiomics plc and contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 100 projects, involving over 50 targets and 75 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.